{"id":820747,"date":"2025-03-03T13:33:47","date_gmt":"2025-03-03T18:33:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/"},"modified":"2025-03-03T13:33:47","modified_gmt":"2025-03-03T18:33:47","slug":"investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/","title":{"rendered":"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, March  03, 2025  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of <strong>Pacira BioSciences, Inc. (NASDAQ: PCRX).<\/strong><\/p>\n<p>Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T449HuJfcTA5rPaIQs4G_MxKgfT2EEKK3KBIAJV9JmqvCMJelzN2lNnP-eZ6JP8EGZaIefIz_D2Me3EcnCC_CohtenpqUHE5XLzhrXKPwyPs7EgbLKe8RePRgCse1nFL5_K_jrG1f4es9qE0IXCtclat4HAEup6VIkvo2693AeaaNk1CJVU9_lqeL1K6wXlb3SmSajRv3-9F1sJpDa1LF_5PVFa4dz3goBMeXr_GSZBd9j9oowmUcIHwxf6oaO_Fl2zbAokFfnKN93RvKTlnALR06UNli2jaw47mFzys2H5dxjKRcUnf0wKKYEPGd8kH\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/pacira-biosciences-inc-loss-submission-form\/?id=132992&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>August 2, 2023 to August 8, 2024<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court \u201cfound that the company\u2019s U.S. Patent No. 11,033,495 (the \u2018495 patent) is not valid,\u201d and, thus, eVenus is not infringing on anything. Pacira\u2019s \u2018495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the \u2018495 patent calls into question the validity of the Company\u2019s other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward. Following this news, Pacira\u2019s common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira\u2019s stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day.<\/p>\n<p>\n        <strong>DEADLINE: March 14, 2025<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T449HuJfcTA5rPaIQs4G_MxKgfT2EEKK3KBIAJV9JmqvCMJelzN2lNnP-eZ6JP8EGZaIefIz_D2Me3EcnCC_CohtenpqUHE5XLzhrXKPwyPs7EgbLKe8RePRgCse1nFL5_K_jrG1f4es9qE0IXCtctcpbSIpcx3sq1KmNQHsZlrU1tmvzQ8oEGwGV6F_SmKnLV96gd_AIaN2_hxjok9HbvOYvtjJpcWeLsNqRx3ajYSPN7s2wEYmaTdYkx9hHzjRX-S5aQ8wRjXSD1DhWfsEjs-6JhHmphqc268hdZdOl5vpgIQjuCqe6mslWhJuDvqV\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/pacira-biosciences-inc-loss-submission-form\/?id=132992&amp;from=3<\/a><\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of PCRX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 14, 2025. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=saVR_FZPs9Ii0J9vF0bhO1d9QhMQOgGhNIpYCUWpH4iG8y8Z-8LyjVyaHCvPUKato_jSK3WC2VnQpnVIUp31sIwDYvQnNvrmijXegRo-Xxt9LCnkZtNLysd0YR3YmVAx\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a><br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Mzk0ZjhlMGEtZWFiYi00OWU1LThiZDUtYjVkZjM0MGU0N2I2LTEyNzA0Njc=\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/pacira-biosciences-inc-loss-submission-form\/?id=132992&amp;from=3 CLASS PERIOD: August 2, 2023 to August 8, 2024 ALLEGATIONS: According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court \u201cfound that the company\u2019s U.S. Patent No. 11,033,495 (the \u2018495 patent) is not valid,\u201d and, thus, eVenus is not &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-820747","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/pacira-biosciences-inc-loss-submission-form\/?id=132992&amp;from=3 CLASS PERIOD: August 2, 2023 to August 8, 2024 ALLEGATIONS: According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court \u201cfound that the company\u2019s U.S. Patent No. 11,033,495 (the \u2018495 patent) is not valid,\u201d and, thus, eVenus is not &hellip; Continue reading &quot;Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T18:33:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX\",\"datePublished\":\"2025-03-03T18:33:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/\"},\"wordCount\":447,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/\",\"name\":\"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=\",\"datePublished\":\"2025-03-03T18:33:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/","og_locale":"en_US","og_type":"article","og_title":"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX - Market Newsdesk","og_description":"NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/pacira-biosciences-inc-loss-submission-form\/?id=132992&amp;from=3 CLASS PERIOD: August 2, 2023 to August 8, 2024 ALLEGATIONS: According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court \u201cfound that the company\u2019s U.S. Patent No. 11,033,495 (the \u2018495 patent) is not valid,\u201d and, thus, eVenus is not &hellip; Continue reading \"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-03T18:33:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX","datePublished":"2025-03-03T18:33:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/"},"wordCount":447,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/","name":"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=","datePublished":"2025-03-03T18:33:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0NCM2Nzg1MDMyIzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-pacira-biosciences-inc-should-contact-the-gross-law-firm-before-march-14-2025-to-discuss-your-rights-pcrx-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights \u2013 PCRX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=820747"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820747\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=820747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=820747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=820747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}